Piramal Pharma Limited announced the approval of its unaudited financial results for the first quarter ended June 30, 2026. The Board of Directors, in their meeting held on July 29, 2026, greenlit both standalone and consolidated results. Key financial highlights for the quarter include ₹1,239.58 Crores in standalone total income and ₹2,359.33 Crores in consolidated total income.
Piramal Pharma Announces Q1 FY27 Results
Piramal Pharma Limited has officially released its unaudited financial results for the first quarter of the financial year ending June 30, 2026. The company’s Board of Directors convened on July 29, 2026, to review and approve these results, which encompass both standalone and consolidated financial statements.
Standalone Financial Highlights (Q1 FY27)
For the quarter ended June 30, 2026, Piramal Pharma Limited reported a standalone total income of ₹1,239.58 Crores. The profit before tax stood at ₹149.48 Crores, with a net profit after tax of ₹113.48 Crores. These figures reflect the operational performance of the company on a standalone basis for the period.
Consolidated Financial Highlights (Q1 FY27)
On a consolidated basis, the Group reported a total income of ₹2,359.33 Crores for the quarter ending June 30, 2026. The consolidated profit before tax was ₹43.00 Crores, and the net profit/(loss) after tax amounted to (₹69.39) Crores. The consolidated results also incorporate the financial performance of its subsidiaries.
Other Comprehensive Income
The company also disclosed its Other Comprehensive Income/(Loss) (OCI) for the quarter. On a standalone basis, the OCI was (₹5.00) Crores. Consolidated, the OCI was (₹30.55) Crores. These figures represent changes in equity that do not arise from ordinary business activities.
Audit and Review Process
The unaudited standalone and consolidated financial results have undergone a limited review by the statutory auditors, Suresh Surana & Associates LLP. The Audit Committee reviewed the results, and the Board of Directors approved them. The limited review provides assurance that the financial statements are free from material misstatement.
Information Availability
The financial results are also accessible on the company’s official website, www.piramalpharma.com, in compliance with regulatory requirements. The Board meeting commenced at 5:30 pm and concluded at 8:30 pm on July 29, 2026.
Source: BSE
